1) PRL001 Costello (2019) “The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer”. Oncogen 2:(3). (link)

2) PRL002 Levina et al. (2009) “Biological Significance of Prolactin in Gynecological Cancers” Cancer Research 69(12): 5226–5233. (link)

3) PRL003 Chou et al. (2021) “Regulation of extracellular and intracellular prolactin on cell proliferation and survival rate through GHR/JAK2/STAT3 pathway in NSCLC” Chemosphere 269:129625. (link)

4) PRL004 Sa-nguanraksa et al. (2020) “The role of Prolactin/Prolactin Receptor polymorphisms and expression in breast cancer susceptibility and outcome” Translational Cancer Research 9(10):6344-6353. (link)

5) PRL005 Sa-nguanraksa et al. (2021) “Expression of long-form prolactin receptor is associated with lower disease-free and overall survival in node-negative breast cancer patients». Gland Surgery 10(1):130-142. (link)

6) PRL006 Ding et al. (2017) “Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy”. Endocrinology 158(6): 1595–1611. (link)

7) PRL007 da Silva et al. (2015) “Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling”. Frontiers in Endocrinology 6:186. (link)

8) PRL008 Kavarthapu et al. (2021) “Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer.” Cancers 2021: 13, 4685. (link)

9) PRL009 Fei et al. (2017) “Sex-related hormone receptor in laryngeal squamous cell carcinoma: correlation with androgen estrogen-ɑ and prolactin receptor expression and influence of prognosis”. Acta Oto-Laryngologica 138(1): 66-72. (link)

10) PRL010 Harbaum et al. (2010) “Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases”. Modern Pathology 23; 961-971. (link)

11) PRL011 Hathaway et al. (2021) “Prolactin and Risk of Epithelial Ovarian Cancer”. Cancer epidemiology, biomarkers & prevention 30(9):1652-1659. (link)

12) PRL012 Sethi et al. (2012) “Prolactin and cancer: Has the orphan finally found a home?” Indian Journal of Endocrinology and Metabolism16(Suppl 2): S195–S198. (link)

13) PRL013 Caponnetto et al. (2017) “Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab” Oncology 93(1):62-66. (link)

14) PRL014 Kresovich et al. (2024) “Prolattina plasmatica e rischio di cancro al seno in postmenopausa: un’analisi combinata di quattro studi prospettici di coorte – Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies” (link)